- Previous Close
0.8900 - Open
0.8900 - Bid 0.8461 x 100
- Ask 0.9312 x 100
- Day's Range
0.8495 - 0.9200 - 52 Week Range
0.7040 - 11.4100 - Volume
261,503 - Avg. Volume
954,352 - Market Cap (intraday)
40.466M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8400 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.33
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
www.verrica.comRecent News: VRCA
View More
Performance Overview: VRCA
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRCA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRCA
View MoreValuation Measures
Market Cap
40.58M
Enterprise Value
64.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.50
Price/Book (mrq)
238.54
Enterprise Value/Revenue
7.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-71.41%
Return on Equity (ttm)
-2,059.89%
Revenue (ttm)
9.21M
Net Income Avi to Common (ttm)
-84.99M
Diluted EPS (ttm)
-1.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
22.96M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-31.81M
Research Analysis: VRCA
View MoreCompany Insights: VRCA
VRCA does not have Company Insights
Research Reports: VRCA
View MoreDaily – Vickers Top Buyers & Sellers for 07/25/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 07/06/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/08/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.